Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 8/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.44 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30416644 | 0.91 | ALDH1A1 (0.42) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL21381604 | 0.91 | ALDH1A1 (0.42) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL30633571 | 0.84 | RAB9A (0.36) | CYP1A2 | |
| SCHEMBL14239619 | 0.83 | TSHR (0.42) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL24618223 | 0.81 | OPRM1 (0.43) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL24618224 | 0.80 | OPRM1 (0.42) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL9989158 | 0.77 | AKR1C1 (0.39) | — | |
| SCHEMBL10696393 | 0.77 | OPRM1 (0.50) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL15321526 | 0.75 | CTDSP1 (0.47) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL5169008 | 0.75 | MEN1 (0.51) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034111-A1 | NOVEL HETEROCYCLES AS sPLA2-X INHIBITORS | CAYMAN CHEMICAL COMPANY INCORPORATED (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4561991-A1 | NOVEL HETEROCYCLES AS SPLA2-X INHIBITORS | Cayman Chemical Company, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2024026290-A1 | NOVEL HETEROCYCLES AS sPLA2-X INHIBITORS | CAYMAN CHEMICAL COMPANY INCORPORATED (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024026290-A1 | NOVEL HETEROCYCLES AS sPLA2-X INHIBITORS | CAYMAN CHEMICAL COMPANY INCORPORATED (US) | 2024-02-01 | — | — | WO | disclosed |
| US-20230167119-A1 | DIAMINOPYRAZOLO[1,5-A]PYRIMIDINE-6-CARBONITRILE COMPOUNDS AS ADENOSINE 2A RECEPTOR AND ADENOSINE 2B RECEPTOR ANTAGONIST | Bugworks Research, Inc. | 2023-06-01 | — | — | US | disclosed |
| US-20230167119-A1 | DIAMINOPYRAZOLO[1,5-A]PYRIMIDINE-6-CARBONITRILE COMPOUNDS AS ADENOSINE 2A RECEPTOR AND ADENOSINE 2B RECEPTOR ANTAGONIST | Bugworks Research, Inc. | 2023-06-01 | — | — | US | disclosed |
| WO-2022149167-A1 | DIAMINOPYRAZOLO[1,5-A]PYRIMIDINE-6-CARBONITRILE COMPOUNDS AS ADENOSINE 2A RECEPTOR AND ADENOSINE 2B RECEPTOR ANTAGONIST | BUGWORKS RESEARCH INDIA PVT LTD (IN) | 2022-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034111-A1 | NOVEL HETEROCYCLES AS sPLA2-X INHIBITORS | PLA2G2F, PLA2R1, PLA2G12A | OPRM1 2041/4885OPRD1 1791/4885OPRK1 1830/4885 |
| US-20230167119-A1 | DIAMINOPYRAZOLO[1,5-A]PYRIMIDINE-6-CARBONITRILE COMPOUNDS AS ADENOSINE 2A RECEPTOR AND ADENOSINE 2B RECEPTOR ANTAGONIST | ADORA2A, ADORA2B, ADORA1 | OPRM1 165/4885OPRD1 410/4885OPRK1 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.